Holen Sie sich die Stockscreener-App
35.42
1.17%
-0.42
Schlusskurs vom Vortag:
$35.84
Offen:
$35.68
24-Stunden-Volumen:
115.59K
Relative Volume:
0.23
Marktkapitalisierung:
$981.52M
Einnahmen:
$3.25M
Nettoeinkommen (Verlust:
$-116.80M
KGV:
-11.61
EPS:
-3.05
Netto-Cashflow:
$-98.17M
1W Leistung:
+4.76%
1M Leistung:
+6.49%
6M Leistung:
+264.03%
1J Leistung:
+144.61%
1-Tages-Spanne:
$34.80
$35.70
1-Wochen-Bereich:
$33.94
$37.75
52-Wochen-Spanne:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Firmenname
Rapt Therapeutics Inc
Sektor
Branche
Telefon
(650) 489-9000
Adresse
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RAPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
35.42 | 993.16M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-26 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-11-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2024-02-21 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-09-14 | Eingeleitet | Berenberg | Buy |
| 2023-08-09 | Eingeleitet | Stifel | Buy |
| 2023-06-15 | Eingeleitet | Barclays | Overweight |
| 2023-01-04 | Eingeleitet | Guggenheim | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | CapitalOne | Overweight |
| 2022-05-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2021-08-12 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-21 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-11-25 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-11-25 | Eingeleitet | UBS | Buy |
| 2019-11-25 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Rapt Therapeutics Inc Aktie (RAPT) Neueste Nachrichten
Can RAPT Therapeutics Inc. stock sustain institutional interestSupport and Resistance Levels & Budget Friendly Trading Ideas - bollywoodhelpline.com
RAPT Therapeutics (RAPT) Is Up 8.0% After Index Additions And Trial Progress News Has The Bull Case Changed? - simplywall.st
RAPT Therapeutics (RAPT) Joins Key Biotech Index Is Its Investor Story Entering a New Phase? - Yahoo Finance
Rapt Therapeutics (NASDAQ:RAPT) Trading 9.8% HigherWhat's Next? - MarketBeat
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Can RAPT Therapeutics Inc. (0RA0) stock resist broad market declinesQuarterly Growth Report & Safe Entry Zone Identification - Улправда
TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a “Buy” - Insider Monkey
TD Cowen Initiates Coverage on RAPT Therapeutics (RAPT) with a "Buy" - Finviz
Certain Pre Funded warrants of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Certain Options of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Certain Common Stock of RAPT Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2025. - marketscreener.com
Is RAPT Therapeutics Inc. (0RA) stock a top dividend aristocrat candidateRisk Management & Free Daily Entry Point Trade Alerts - Улправда
Will RAPT Therapeutics Inc. stock outperform value stocksJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Will RAPT Therapeutics Inc. stock deliver long term returnsJuly 2025 Trends & Free Community Consensus Stock Picks - Улправда
Is RAPT Therapeutics Inc. (0RA) stock among top earnings playsMarket Performance Summary & Stepwise Swing Trade Plans - ulpravda.ru
Published on: 2025-12-19 09:56:31 - Улправда
How RAPT Therapeutics Inc. stock benefits from global expansionWeekly Stock Recap & AI Driven Stock Movement Reports - Улправда
Published on: 2025-12-19 01:07:45 - Улправда
Why analysts maintain buy rating on RAPT Therapeutics Inc. (0RA0) stockInsider Buying & Accurate Buy Signal Alerts - Улправда
Rapt Therapeutics (NASDAQ:RAPT) Shares Gap UpStill a Buy? - MarketBeat
Will RAPT Therapeutics Inc. stock maintain dividend yieldJuly 2025 Gainers & Real-Time Buy Signal Notifications - ulpravda.ru
TD Cowen Initiates Coverage on RAPT Therapeutics With Buy Rating - marketscreener.com
Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated at TD Cowen - MarketBeat
TD Cowen initiates coverage on Rapt Therapeutics stock with Buy rating - Investing.com Canada
Rapt Therapeutics (NASDAQ:RAPT) Stock Price Down 9.2%Should You Sell? - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) surges 5.3%; individual investors who own 34% shares profited along with institutions - Yahoo Finance
Rapt Therapeutics (NASDAQ:RAPT) Trading Up 4.9%Here's Why - MarketBeat
BVF Inc. IL Trims Holdings in Rapt Therapeutics $RAPT - MarketBeat
RAPT Therapeutics Announces Major Public Stock Offering - MSN
Rapt Therapeutics $RAPT Shares Sold by Redmile Group LLC - MarketBeat
Can RAPT Therapeutics Inc. (0RA) stock deliver strong annual returnsMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-04 13:14:54 - Newser
How RAPT Therapeutics Inc. (0RA) stock compares with tech leadersPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
How robust is RAPT Therapeutics Inc. (0RA) stock financial positionVolume Spike & Risk Managed Trade Strategies - Newser
Does RAPT Therapeutics Inc (RAPT) offer a good opportunity for investors? - Setenews
Can RAPT Therapeutics Inc. (0RA0) stock sustain margin levels2025 Biggest Moves & Fast Moving Market Watchlists - Newser
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherRecession Risk & Fast Exit/Entry Strategy Plans - Newser
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaFed Meeting & Safe Capital Allocation Plans - Newser
How RAPT Therapeutics Inc. (0RA0) stock performs in easing cyclesRisk Management & Technical Pattern Based Buy Signals - Newser
Published on: 2025-12-02 05:12:24 - Newser
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycle2025 Big Picture & Growth Oriented Trade Recommendations - Newser
RAPT Therapeutics announces planned departure of chief medical officer - Investing.com India
RAPT Therapeutics announces planned departure of chief medical officer By Investing.com - Investing.com Nigeria
RAPT Therapeutics Announces CMO Departure - TipRanks
RAPT Therapeutics Announces Departure of Chief Medical Officer - TradingView
Are Smart Investors Making the Right Decision? RAPT Therapeutics Inc (RAPT) - Setenews
Finanzdaten der Rapt Therapeutics Inc-Aktie (RAPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):